Photo of Hagen Kennecke from ohsu.edu
Jul 10, 2024, 15:30
Hagen Kennecke: First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated colon cancer
Hagen Kennecke, Section chief and Chief Health Officer of the OHSU Knight-Legacy Health Cancer Collaborative, shared a post on X:
”First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated colon cancer, OS HR=0.4.
Patients are asking: do we recommend COX-2 for the 20% with mutation PIK3CA?
Need to do NGS for all stage III CRC.”
Source: Hagen Kennecke/X
Anthony F Shields
Ardaman Shergill
Benjamin Tan
cancer
Chao Ma
Charles S Fuchs
Colon cancer
Eileen M. O'Reilly
Felix Couture
Hagen Kennecke
James Knight
Jeffrey A Meyerhardt
Jonathan A Nowak
Juha Väyrynen
Kenji Fujiyoshi
Koichiro Haruki
Melissa Zhao
OncoDaily
Oncology
Pankaj Kumar
Philip Kuebler
Philip Philip
Qian Shi
Shrikant Mane
Shuji Ogino
Smitha Krishnamurthi
Tyler Twombly
Jul 15, 2024, 21:23